{
    "root": "795c3e14-2ce3-4fec-8314-7d593e3990dd",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Tafinlar",
    "value": "20250307",
    "ingredients": [
        {
            "name": "DABRAFENIB MESYLATE",
            "code": "B6DC89I63E"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "ACESULFAME POTASSIUM",
            "code": "23OV73Q5G9"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        }
    ],
    "indications": "tafinlar kinase inhibitor indicated single agent treatment patients unresectable metastatic melanoma braf v600e mutation detected fda-approved test . ( 1.1 , 2.1 ) tafinlar indicated , combination trametinib , : treatment patients unresectable metastatic melanoma braf v600e v600k mutations detected fda-approved test . ( 1.2 , 2.1 ) adjuvant treatment patients melanoma braf v600e v600k mutations , detected fda-approved test , involvement lymph node ( ) , following complete resection . ( 1.3 , 2.1 ) treatment patients metastatic non-small cell lung cancer ( nsclc ) braf v600e mutation detected fda-approved test . ( 1.4 , 2.1 ) treatment patients locally advanced metastatic anaplastic thyroid cancer ( atc ) braf v600e mutation , detected fda-approved test , satisfactory locoregional treatment options . ( 1.5 , 2.1 ) treatment adult pediatric patients 1 year age older unresectable metastatic solid tumors braf v600e mutation progressed following prior treatment satisfactory alternative treatment options . indication approved accelerated approval based overall response rate ( orr ) duration response ( dor ) . continued approval indication may contingent upon verification description benefit confirmatory trial ( ) . ( 1.6 , 2.1 ) treatment pediatric patients 1 year age older low-grade glioma ( lgg ) braf v600e mutation require systemic therapy . ( 1.7 , 2.1 ) limitations : tafinlar indicated treatment patients colorectal cancer known intrinsic resistance braf inhibition . ( 1.8 , 12.1 ) tafinlar indicated treatment patients wild-type braf solid tumors . ( 5.2 )",
    "contraindications": "recommended tafinlar adult patients 150 mg ( two 75 mg capsules ) orally twice daily . recommended tafinlar pediatric patients based body weight . take tafinlar least 1 hour least 2 hours meal . ( 2 )",
    "warningsAndPrecautions": "tafinlar capsules : 50 mg capsules : dark red capsule imprinted \u2018 gs tew \u2019 \u2018 50 mg \u2019 available bottles 120 child-resistant closures ( ndc 0078-0682-66 ) . bottle contains silica gel desiccant . 75 mg capsules : dark pink capsule imprinted \u2018 gs lhf \u2019 \u2018 75 mg \u2019 available bottles 120 child-resistant closures ( ndc 0078-0681-66 ) . bottle contains silica gel desiccant . store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . store dispense original bottle desiccant . tafinlar tablets oral suspension : 10 mg tablets oral suspension : white slightly yellow , round biconvex 6 mm tablet debossed \u201c \u201d one side \u201c nvr \u201d side . available bottles 210 child-resistant closures ( ndc 0078-1154-21 ) . bottle contains 2 silica gel desiccants . store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . store dispense original bottle desiccant .",
    "adverseReactions": "none .",
    "indications_original": "TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.8 , 12.1 ) TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )",
    "contraindications_original": "The recommended dosage of TAFINLAR in adult patients is 150 mg (two 75 mg capsules) orally twice daily. The recommended dosage for TAFINLAR in pediatric patients is based on body weight. Take TAFINLAR at least 1 hour before or at least 2 hours after a meal. ( 2 )",
    "warningsAndPrecautions_original": "TAFINLAR Capsules:\n                  50 mg capsules: Dark red capsule imprinted with \u2018GS TEW\u2019 and \u201850 mg\u2019 available in bottles of 120 with child-resistant closures (NDC 0078-0682-66). Each bottle contains a silica gel desiccant.\n                  75 mg capsules: Dark pink capsule imprinted with \u2018GS LHF\u2019 and \u201875 mg\u2019 available in bottles of 120 with child-resistant closures (NDC 0078-0681-66). Each bottle contains a silica gel desiccant.\n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature]. Store and dispense in the original bottle with the desiccant.\n                  TAFINLAR Tablets for Oral Suspension:\n                  10 mg tablets for oral suspension: white to slightly yellow, round biconvex 6 mm tablet debossed with \u201cD\u201d on one side and \u201cNVR\u201d on the other side. Available in bottles of 210 with child-resistant closures (NDC 0078-1154-21). Each bottle contains 2 silica gel desiccants.\n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature]. Store and dispense in the original bottle with the desiccant.",
    "adverseReactions_original": "None."
}